An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received ≥2 prior therapies

Marco Montillo, Ian Flinn, Matthew Davids, Peter Hillmen, Julio Delgado, Bryone Kuss, Constantine Tam, Ulrich Jager, Paolo Ghia, Stephan Stilgenbauer, Stephanie Lustgarten, David T. Weaver, Hagop Youssoufian, Florence Cymbalista

Research output: Contribution to journalMeeting Abstractpeer-review

Abstract

Despite effective frontline therapies, many patients (pts) with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) eventually relapse and require additional therapies to control their disease. Duvelisib (DUV), a first-in-class oral dual PI3K-δ,γ inhibitor, was approved by the FDA for the treatment of relapsed or refractory (R/R) CLL or SLL after ≥2 prior therapies. Here we present the efficacy
and safety of DUV in pts with R/R CLL or SLL who had received ≥2 prior therapies in the phase 3 DUO trial (NCT02004522).
Original languageEnglish
Pages (from-to)116-117
Number of pages2
JournalLeukemia and Lymphoma
Volume61
Issue numberS1
DOIs
Publication statusPublished - 21 May 2020
EventXVIII International Workshop on Chronic Lymphocytic Leukemia - EICC: Edinburgh International Conference Centre, Edinburgh, United Kingdom
Duration: 20 Sep 201923 Sep 2019
https://www.iwcll2019.org/ (Conference website)

Keywords

  • Duvelisib
  • chronic lymphocytic leukemia
  • small lymphocytic lymphoma
  • Prior therapy
  • inhibitor
  • relapse prevention

Fingerprint

Dive into the research topics of 'An improved benefit-risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received ≥2 prior therapies'. Together they form a unique fingerprint.

Cite this